Platelets of patients with chronic kidney disease demonstrate deficient platelet reactivity in vitro

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Van Bladel, Esther R ^a   De Jager, Rosa L ^b   Walter, Daisy ^a   Cornelissen, Loes ^a   Gaillard, Carlo A ^b,c   Boven, Leonie A ^b   Roest, Mark ^a   Fijnheer, Rob ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MEANDER MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiorenal syndrome; End stage renal disease; Haemodialysis; Platelet activation

Indexed keywords

ADENOSINE DIPHOSPHATE; C REACTIVE PROTEIN; PADGEM PROTEIN; PEPTIDE; THROMBIN RECEPTOR ASSOCIATED PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL SURFACE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STAINING; STIMULATION; THROMBOCYTE ACTIVATION;

AGED; AGED, 80 AND OVER; BLOOD PLATELETS; CELLS, CULTURED; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84866636339     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-127     Document Type: Article

References (24)

1. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, Kuller LH, Newman AB, J Am Coll Cardiol 2003 41 1364 1372 10.1016/S0735-1097(03)00163-3 12706933 (Pubitemid 36438998)
2. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY, N Engl J Med 2004 351 1296 1305 10.1056/NEJMoa041031 15385656 (Pubitemid 39268908)
3. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW, Circulation 2003 108 2154 2169 10.1161/01.CIR.0000095676.90936.80 14581387 (Pubitemid 37337595)
4. Platelet dysfunction and end-stage renal disease. Kaw D, Malhotra D, Semin Dial 2006 19 317 322 10.1111/j.1525-139X.2006.00179.x 16893410 (Pubitemid 44091707)
5. Disorders of hemostasis associated with chronic kidney disease. Jalal DI, Chonchol M, Targher G, Semin Thromb Hemost 2010 36 34 40 10.1055/s-0030-1248722 20391294
6. Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Moal V, Brunet P, Dou L, Morange S, Sampol J, Berland Y, Nephrol Dial Transplant 2003 18 1834 1841 10.1093/ndt/gfg185 12937232 (Pubitemid 37098556)
7. Uremic bleeding: closing the circle after 30years of controversies? Noris M, Remuzzi G, Blood 1999 94 2569 2574 10515859 (Pubitemid 29477284)
8. Hemostatic changes in patients with end stage renal disease undergoing hemodialysis. Rios DR, Carvalho MG, Lwaleed BA, Silva AC Se, Borges KB, Dusse LM, Clin Chim Acta 2010 411 135 139 10.1016/j.cca.2009.11.022 19945449
9. Chronic kidney disease and cardiovascular disease in the Medicare population. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA, Kidney Int Suppl 2003 87 24 S31 14531770
10. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Kidney Int 2002 62 1402 1407 10.1111/j.1523-1755.2002.kid571.x 12234312
11. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. Muntner P, He J, Hamm L, Loria C, Whelton PK, J Am Soc Nephrol 2002 3 745 753 (Pubitemid 34183941)
12. Pathogenesis and therapeutic implications of cardiorenal syndrome. Nitta K, Clin Exp Nephrol 2011 15 187 194 10.1007/s10157-010-0374-0 21104421
13. Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease: a potential contributor to cardiovascular risk. Aggarwal A, Kabbani SS, Rimmer JM, Gennari FJ, Taatjes DJ, Sobel BE, Schneider DJ, Am J Kidney Dis 2002 40 315 322 10.1053/ajkd.2002.34510 12148104 (Pubitemid 34827649)
14. Prediction of creatinine clearance from serum creatinine. Cockcroft DW, Gault MH, Nephron 1976 16 31 41 10.1159/000180580 1244564
15. Erythropoietin treatment in patients with combined heart and renal failure: objectives and design of the EPOCARES study. van der Putten K, Jie KE, Emans ME, Verhaar MC, Joles JA, Cramer MJ, Velthuis BK, Meiss L, Kraaijenhagen RJ, Doevendans PA, Braam B, Gaillard CA, J Nephrol 2010 23 4 363 368 20383871
16. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, ESC Committee for Practice Guidelines (CPG), Eur J Heart Fail 2008 10 933 989 10.1016/j.ejheart.2008.08.005 18826876
17. Up-regulation of platelet activation in hemophilia A. van Bladel ER, Roest M, de Groot PG, Schutgens RE, Haematologica 2011 96 888 895 10.3324/haematol.2011.042663 21422116
18. Evidence for an increased generation of prostacyclin in the microvasculature and an impairment of the platelet alpha-granule release in chronic renal failure. Kyrle PA, Stockenhuber F, Brenner B, Gössinger H, Korninger C, Pabinger I, Sunder-Plassmann G, Balcke P, Lechner K, Thromb Haemost 1988 60 205 208 2975407
19. Electron microscopic observation in case of platelet activation in a chronic haemodialysis subject. Schoorl M, Bartels PCM, Gritters M, Fluitsma D, Musters R, Nubé MJ, Hematol Rep 2011 3 15 22184536
20. High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood. Zwaginga JJ, IJsseldijk MJ, Beeser-Visser N, De Groot PG, Vos J, Sixma JJ, Blood 1990 75 1498 1508 2156581 (Pubitemid 20114890)
21. Thrombosis in end-stage renal disease. Casserly LF, Dember LM, Semin Dial 2003 16 245 256 10.1046/j.1525-139X.2003.16048.x 12753687 (Pubitemid 37363225)
22. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease. A systematic review and meta-analysis. Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Copetti M, Graziano G, Tognoni G, Jardine M, Webster A, Nicolucci A, Zoungas S, Strippoli GF, Ann Intern Med 2012 156 445 459 22431677
23. Hemodialysis, erythropoietin and megakaryocytopoiesis: factors in uremic thrombocytopathy and thrombophilia. Zwaginga JJ, J Thromb Haemost 2004 2 8 1272 1274 10.1111/j.1538-7836.2004.00839.x 15304030 (Pubitemid 40186121)
24. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Stumpf C, Lehner C, Eskafi S, Raaz D, Yilmaz A, Ropers S, Schmeisser A, Ludwig J, Daniel WG, Garlichs CD, Eur J Heart Fail 2003 5 629 637 10.1016/S1388-9842(03)00110-7 14607202 (Pubitemid 38043968)